Back to Search Start Over

Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment

Authors :
Xupu Wang
Lizheng Wang
Wenmo Liu
Xinyao Liu
Xinyuan Jia
Xinyao Feng
Fangshen Li
Rui Zhu
Jiahao Yu
Haihong Zhang
Hui Wu
Jiaxin Wu
Chu Wang
Bin Yu
Xianghui Yu
Source :
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-21 (2023)
Publication Year :
2023
Publisher :
BMC, 2023.

Abstract

Abstract Background In addition to specifically inducing tumor cell apoptosis, recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has also been reported to influence the cancer immune microenvironment; however, its underlying effects and mechanisms remain unclear. Investigating the immunomodulatory effects and mechanisms of recombinant TRAIL in the tumor microenvironment (TME) may provide an important perspective and facilitate the exploration of novel TRAIL strategies for tumor therapy. Methods Immunocompetent mice with different tumors were treated with three doses of recombinant TRAIL, and then the tumors were collected for immunological detection and mechanistic investigation. Methodological approaches include flow cytometry analysis and single-cell sequencing. Results In an immunocompetent mouse model, recombinant soluble mouse TRAIL (smTRAIL) had dose-related immunomodulatory effects. The optimal dose of smTRAIL (2 mg/kg) activated innate immune cells and CD8+ T cells, whereas higher doses of smTRAIL (8 mg/kg) promoted the formation of a tumor-promoting immune microenvironment to counteract the apoptotic effects on tumor cells. The higher doses of smTRAIL treatment promoted M2-like macrophage recruitment and polarization and increased the production of protumor inflammatory cytokines, such as IL-10, which deepened the suppression of natural killer (NK) cells and CD8+ T cells in the tumor microenvironment. By constructing an HU-HSC-NPG.GM3 humanized immune system mouse model, we further verified the immunomodulatory effects induced by recombinant soluble human TRAIL (shTRAIL) and found that combinational administration of shTRAIL and trabectedin, a macrophage-targeting drug, could remodel the tumor immune microenvironment, further enhance antitumor immunity, and strikingly improve antitumor effects. Conclusion Our results highlight the immunomodulatory role of recombinant TRAIL and suggest promising therapeutic strategies for clinical application. Graphical Abstract

Details

Language :
English
ISSN :
17569966
Volume :
42
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Experimental & Clinical Cancer Research
Publication Type :
Academic Journal
Accession number :
edsdoj.fce8144f420e4f5aa9fb6dc3876bc6ce
Document Type :
article
Full Text :
https://doi.org/10.1186/s13046-023-02795-x